BEST UNLIMITED TURBO LONG CERTIFICATE - MEDTRONIC Stock

Certificat

Q668S

DE000SU63BL8

Market Closed - Euronext Paris 12:30:00 2024-05-15 pm EDT
4.235 EUR +0.24% Intraday chart for BEST UNLIMITED TURBO LONG CERTIFICATE - MEDTRONIC
Current month+12.65%
1 month+9.41%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-05-15 4.235 +0.24%
24-05-14 4.225 +0.96%
24-05-13 4.185 +5.02%
24-05-10 3.985 +1.01%
24-05-09 3.945 +2.33%

Real-time Euronext Paris

Last update May 15, 2024 at 12:30 pm EDT

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellCALL
Underlying MEDTRONIC PLC
IssuerLogo Issuer Société Générale Société Générale
Q668S
ISINDE000SU63BL8
Date issued 2024-01-17
Strike 61.45 $
Maturity Unlimited
Parity 5 : 1
Emission price 5.03
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 5.4
Lowest since issue 3.38

Company Profile

Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows: - general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.; - cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.; - vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.; - spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity; - neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%); - diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps; - neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc. Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).
Sector
-
More about the company

Ratings for Medtronic plc

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: Medtronic plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
84.72 USD
Average target price
94.77 USD
Spread / Average Target
+11.87%
Consensus
  1. Stock Market
  2. Certificates
  3. Q668S Certificat
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW